Contact

Contact

Ternion welcomes corrections, questions, and feedback about the site's coverage and editorial approach. If you have updates or concerns, please check the About page for our editorial policies and channels for reaching the project.

Independent resource

We present evidence and uncertainties — not clinical services.

Evidence-first

Content distinguishes investigational claims from established care.

Close-up medical detail photograph used as a contextual hero image for contact page about ibogaine and buprenorphine transitions

How to reach Ternion

At present this site does not publish a direct email address or phone line. The project can be reached through its published channels; please check back for contact details or visit our explanation of editorial practices on the About page to see how we handle corrections and inquiries.

Note: Ternion is an independent information resource, not a clinic or medical provider. Content is not medical or legal advice.

If you prefer to explore related material

For context on ibogaine and transition risk conversations, some readers find external resources helpful: authoritative summaries can be found on encyclopedic pages such as the Ibogaine overview on Wikipedia, and public health perspectives are sometimes available from government health sites like the National Institute on Drug Abuse. Clinical standards are discussed at academic centers such as Johns Hopkins Medicine for substance-use care broadly.

Quick links

Editorial approach

Read about our mission and sourcing on the About page for details on how corrections are handled and who to contact about content concerns.

Site navigation

If you arrived here from another page, return to our main collection of materials through the site's front page by following the contextual link back to the main page.